噻托溴铵联合茚达特罗治疗慢性阻塞性肺病患者的疗效及对血管内皮功能的影响-东南大学学报医学版

噻托溴铵联合茚达特罗治疗慢性阻塞性肺病患者的疗效及对血管内皮功能的影响

单位：四川省人民医院呼吸科, 四川成都 610072

分类号：R563

出版年·卷·期（页码）：2018·37·第二期（255-259）

摘要：

目的：探究茚达特罗联合噻托溴铵治疗慢性阻塞性肺病（COPD）患者的疗效及对血管内皮功能的影响。方法：选取2014年3月至2016年1月收治的COPD稳定期B、C级患者86例，随机分为对照组和联合组，对照组给予茚达特罗吸入治疗，联合组给予茚达特罗联合噻托溴铵吸入治疗，连续用药1年。比较两组治疗前、治疗6个月、治疗12个月后肺功能、生活质量评分、血管内皮功能的变化以及治疗期间急性加重情况。结果：联合组、对照组治疗6、12个月后第1秒用力呼气量（FEV₁）、用力肺活量（FVC）、FEV₁/FVC、深吸气量、生活质量评分较治疗前明显改善（P<0.05），且联合组优于对照组（P<0.05）；治疗6、12个月后联合组、对照组血管性血友病因子、内皮素1水平较治疗前均明显降低（P<0.05），血管内皮生长因子、一氧化氮水平均明显上升（P<0.05），且联合组优于对照组（P<0.05）；联合组治疗期间急性加重人数和次数明显低于对照组（P<0.05），两组不良反应发生率差异无统计学意义（P>0.05）。结论：茚达特罗联合噻托溴铵治疗稳定期COPD临床疗效较好且安全性良好，同时可有效改善血管内皮功能。

Objective:To investigate the effect of indacaterol combined with tiotropium in the treatment of chronic obstructive pulmonary disease (COPD) and its influence on vascular endothelial function. Methods:A total of 86 patients in the stable phase of COPD in B and C grade from March 2014 to January 2016 were enrolled and were randomly divided into control group and combination group.Control group was given indacaterol while combination group was given indacaterol combined with tiotropium. The courses of treatment in two groups were 1 year. The pulmonary function, CAT scores, vascular endothelial function before treatment and 6 and 12 months after treatment and the situation of acute exacerbation during the treatment were compared. Results:The FEV₁, FVC, FEV₁/FVC, IC and CAT scores between combination group and control group were significantly improved 6 and 12 months after treatment (all P<0.05) and those in combination group were better than those in control group(P<0.05). 6 and 12 months after treatment, the levels of vWf and ET-1 in combination group and control group were significant lower (P<0.05) while the levels of VEGF and NO were significant higher and those in combination group were better than those in control group (P<0.05). The cases and frequency of acute exacerbation in combination group were significant lower than those in control group during the treatment (P<0.05). There was no significant difference in adverse reactions between two groups (P>0.05). Conclusion:Indacaterol combined with tiotropium can improve pulmonary function and quality of life, reduce the number of acute exacerbation with high safety and also improve the vascular endothelial function.

参考文献：

[1] LOPEZCMPOS J L,TAN W,SORIANO J B.Global burden of COPD[J].Respirology,2016,21(1):14-23.
[2] 包鹤龄,方利文,王临虹.1990-2014年中国40岁及以上人群慢性阻塞性肺疾病患病率Meta分析[J].中华流行病学杂志,2016,37(1):119-124.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[4] 吕红,陶政正,范桂芹,等.辛伐他汀治疗慢性阻塞性肺病患者的临床疗效观察[J].现代医学,2017,45(4):575-578.
[5] RINALDI B,DONNIACUO M,SODANO L,et al.Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling[J].Br J Pharmacol,2015,172(14):3627-3637.
[6] TRIFILIEFF A,CHARLTON S J,FAIRHUSRT R A.The preclinical pharmacology of indacaterol[M]//TRIFILIEFF A.Indacaterol.Basel:Springer Basel,2014:25-37.
[7] MASELLI D J,PETERS J I.Review:in COPD,tiotropium improves lung function and reduces adverse events compared with ipratropium bromide[J].Ann Intern Med,2016,164(2):JC6.
[8] MATSUSHIMA S,INUI N,YASUI H,et al.Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease[J].Pulm Pharmacol Ther,2015,30:11-15.
[9] DUGAC A V,RUZIC A,SAMARZIJA M,et al.Persistent endothelial dysfunction turns the frequent exacerbator COPD from respiratory disorder into a progressive pulmonary and systemic vascular disease[J].Med Hypotheses,2015,84(2):155-158.
[10] 陈光宴.内皮素-1、细胞黏附分子-1与慢性阻塞性肺疾病的相关性[J].山东医药,2012,52(47):42-43.
[11] BARTHOLO T P,DA C C,RUFINO R.Evaluation of von Willebrand factor in COPD patients[J].J Bras Pneumol,2014,40(4):373-379.
[12] HARKNESS L M,KANABAR V,SHARMA H S,et al.Pulmonary vascular changes in asthma and COPD[J].Pulm Pharmacol Ther,2014,29(2):144-155.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录